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Introduction: Itch can be perceived differently across patients and it can affect daily life in various ways. It is essential to assess
those aspects that are relevant for the individual patient’s needs to improve treatment of patients suffering from acute or chronic itch.
The International Forum for the Study on Itch (IFSI) Special Interest Group on “Questionnaires” aims to propose tools to assess
different dimensions of itch and improve patient care. As a first step, this study aimed at a systematically reviewing existing patients’
self-report questionnaires on itch.
Materials and methods: The databases PubMed, PsycINFO, and CINAHL were systematically searched for any scientific
publication describing patients’ self-report questionnaires that assess itch-related information (≥ 2 items). Information about the
publication was extracted by 2 experts as well as which of the 14 predefined dimensions of itch (by the IFSI Special Interest Group)
were assessedwithin the questionnaire, for instance, duration of itch, itch aggravating or relieving factors, and effects on quality of life.
Results: From a total of 5282 records, 58 articles were derived describing 62 questionnaires. Over half of the questionnaires were
developed for dermatological conditions, and the vast majority targeted at adults. Most questionnaires address itch-related disability
and itch intensity. Affective qualities of itch, coping with itch, response to current itch treatment, and the opinion on the origin of itch
are infrequently asked for.
Discussion: The number and content of the items within a dimension vary greatly. Measurement properties of the questionnaires
were not systematically addressed, as these were often not reported in the original publication. Future research should focus on
selecting adequate and reliable (sub)scales to develop a modular questionnaire system in order to uniformly assess the individual
patient’s demands and improve care.
Keywords: Itch, Itch dimensions, Pruritus, Questionnaire, PROM, Itch intensity
Introduction
The Special Interest Group (SIG) on itch questionnaires of the
International Forum on the Study of Itch (IFSI) published a
consensus paper[1] giving recommendations on what dimensions
of itch could be assessed in an itch questionnaire in order to assess
itch and, consequently, guide therapy. This is essential because
chronic itch (defined by IFSI as lasting at least 6 wk[2]) is a pre-
valent symptom[3–6] of various conditions, such as dermatoses
(eg, atopic dermatitis, psoriasis, chronic urticaria), systemic (eg,
liver or renal failure), and neurological diseases (eg, postherpetic
neuralgia) or its origin can be multifactorial (for an extensive
classification of chronic itch see Ständer et al[2]). Itch can affect
patients’ quality of life, which, in turn, can also intensify itch[7,8],
making it an interdisciplinary clinical problem and challenge. In
order to adequately help each individual patient, it is essential to
explore various dimensions of the patient’s itch. The following 14
itch dimensions were put forward by the SIG: localization, fre-
quency, duration, intensity, sensory qualities, scratch responses,
opinion on origin, affective qualities, itch aggravating or relieving
factors, disability/impairment, response to current and previous
itch treatments, coping, cognitions, quality of life[1]. The SIG
involved in this subject has the ultimate aim to provide, within an
interdisciplinary team, a template for the use of questionnaires for
different diagnoses that can be applied in a modular manner. To
this end, validated questionnaires are needed.
Various scales, questionnaires, and surveys have been developed
tomeasure itch-related characteristics and itch’ impact on quality of
life. Frequently, only one aspect of the itch sensation has been
assessed, that is mainly the intensity of itch measured with a
Numeric Rating Scale (NRS) or Visual Analogue Scale (VAS)[9–11].
In addition, various questionnaires were developed to primarily
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assess multiple dimensions of itch. Most of these questionnaires
were developed for dermatological diseases, for example, the
Eppendorf Itch Questionnaire (EIQ)[12] and the 5-D-Itch-Scale[13].
Multiple questionnaires within the nondermatological field had a
different primary aim, but often also include itch questions. Some
questionnaires were designed to measure acute itch (<6wk[2]),
others to assess chronic itch. It has been a challenge to document all
itch questionnaires along with their content. Previous reviews
focused on patient-reported outcome measures (PROM) especially
for their use in clinical trials[14,15]. These included not only ques-
tionnaires but also monodimensional scales like the NRS[9,16].
Ständer et al[15,17], provided an overview and additional recom-
mendations for useful PROMs in the treatment of itch.However, to
date, an overview of all existing itch questionnaires, while exam-
ining their content has not yet been made.
This study aimed at creating a systematic overview of which
self-report itch questionnaires (defined by the presence at least 2
items) exist, in any study design or (patient) population, and
which itch dimensions these questionnaires address. This over-
view is the first step to a modular system of itch questionnaires.
Materials and methods
Literature search
A systematic literature searchwas conducted up to 15 June 2018 (no
time limitation for the beginning of the search). To this end, we
searched the databases PubMed, PsycINFO, and CINAHL.We also
includedarticles describingquestionnaires,whichwerementionedby
personal communication or found by hand search. References of
included articles were screened by 1 expert (F.D.) for eligibility; if
questionable a second expert (A.I.M.v.L.) was involved.
The databases were searched for original studies that used itch
questionnaires or questionnaires that included multiple questions on
itch in (a) population(s) of patients suffering from chronic itch. In the
search, itch-related terms were combined with questionnaire-related
terms. Medical Subject Headings [MeSH] terms, or equivalent for the
respective database were used whenever possible, that is, Pruritus,
Surveys and Questionnaires, and Patient Reported Outcome
Measures. These MeSH terms were combined with the following
terms that were searched for in title or abstract: pruritus* or itch*,
questionnaire* or survey* or scale* or patient reported outcome.
Detailed search algorithms for the above-mentioned databases are
shown in Supplementary Table 1, Supplemental Digital Content 1
(http://links.lww.com/ITX/A2).
Eligibility criteria
All titles were screened; abstracts and full texts were also screened
when necessary. We included studies if they met the following
inclusion criteria:
• the article describes the use of a questionnaire (or equiv-
alent, like a scale or survey) inquiring the patients’ itch
characteristics;
• the article describes a questionnaire, not only a single scale (see
Reich et al[9,18] for reviews on single items assessing itch), that
is, it contains at least 2 questions about itch;
• the questionnaire was filled in by the patients and potentially
partly by the clinician;
• the article was full text published in a scientific journal (ie,
dissertations or conference abstracts were excluded);
• the full text article as well as the questionnaire items could be
retrieved; and
• the paper was published in English, German, Japanese, Dutch,
or French.
Data extraction
A prepiloted form was used by one expert (F.D.) to extract the fol-
lowing information about each included questionnaire: Information
about the initial publication of the questionnaire (authors, year), the
study population(s) along with the sample size and mean age of the
sample, and the reported or presumed original language(s) the ques-
tionnaire was developed for. In addition, the length of each ques-
tionnaire was judged as short (≤25 items), medium (26–50 items) or
long (≥51 items). Unclarities were resolved by involvement of a sec-
ond expert (A.I.M.v.L.). Another prepiloted form was used to assess
which of the 14 dimensions of itch as defined in the IFSI SIG itch
questionnaires consensus paper were inquired about in each
questionnaire[1]. Half of these dimensions can be classified within the
category “Characteristics of itch,” that is: localization of itch (Where
on your body do you feel itch?); frequency of itch [Howoften does the
itch occur (eg, once per day, twice perweek, during certain times of the
day, etc.)]; duration of itch—the reference frame of this question can
vary between days and years [For how long have you already had
the itch or for how long has the itch been present? Both for how long
in your life (eg, months or years) and how long it lasts if present
(eg, minutes, hours, days) are taken into account]; intensity of itch
measured by VAS or NRS, or Likert scales (and is your itch getting
better/worse is also taken into account here); sensory qualities of itch
(Which descriptors are applicable to the itch sensation, eg pure itch,
stinging, burning, mixed sensation. What does the itch feel like?);
scratch response (What is your behavioral response when you have
itch? Eg, scratching, rubbing, squeezing, pinching the skin). The other
7 dimensions can be classified within the category “itch in daily life”:
opiniononoriginof the itch (What is thepatient’s personal viewon the
origin of itch symptoms?); affective dimensions (Which descriptors are
applicable to the itch sensation, eg, whether the itch is bothersome or
unbearable); itch aggravating or relieving factors (Whatmakes the itch
better or worse, eg hot water, cold weather?); disability/impairment
(How does the itch affects the patient’s everyday life physically,
including work, social activities, and sleep?); response to current and
previous itch treatments (How effective have drugs and other treat-
ments been to reduce itch?); coping with itch (itch specific coping
styles, eg looking for distraction by doing something else); itch cog-
nitions [Cognitions about itch, such as catastrophizing (eg, I cannot
withstand the itch anymore) and problem focused coping (eg, the itch
will only take oneminute)] andquality of life (Howdoes the itch affect
the patient’s emotional wellbeing). The form assessing the dimensions
of itch was filled out by one expert (F.D.) and checked by a second
expert (A.I.M.v.L.); discrepancies were solved by discussion.
Data synthesis
A synthesis of the extracted data will serve as the overview of the
current itch questionnaires. For each questionnaire, we present
the study population described in the included paper as well as the
mean age of this population. In addition, we report the under-
lying origin of these itch populations in accordance with the
etiological IFSI classification of itch[2]. This classification is
developed for chronic itch and includes 6 different categories
containing dermatological, systemic, neurological, psychoso-
matic, mixed diseases, and diseases of other undetermined origin
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(IFSI category I–VI); questionnaires that were administered in
patient populations not classified according to the clinical clas-
sification of itch by IFSI (eg, students or the general population),
were classified separately. We also analyzed the reported (or
presumed) original language and the length of the questionnaire.
We defined one item as one possible answer and assumed there-
fore 4 groups: very short (2–4 items), short (5–25 items), medium
(26–50 item), and long (≥ 51 items).
Results
Study selection
In total we identified 5754 records in the three databases, after
removing duplicates, 5282 records remained (for flow diagram
see Fig. 1 and for overview of the included questionnaires see
Table 2). Ten additional papers describing questionnaires were
found by hand search or by personal communication. Of these
5282 records, 795 abstracts and 251 full texts were screened. In
total, we excluded 64 records, because the concerning ques-
tionnaire did not assess itch at all (eg, theDLQI[19]) or because the
questionnaire did not assess characteristics of itch at all (eg, the
patient-relevant benefit in the treatment of pruritus[20]), 119
articles because of various reasons (eg, only a single item on itch
was assessed, eg the VAS or NRS[9,11] or the questionnaire was
already included). Also, 10 questionnaires could not be included
because information relevant for this review was lacking for the
respective questionnaire because it could not be derived from the
publication and/or the questionnaire itself could not be
obtained[21–30]. We identified 58 relevant articles with in total 62
itch questionnaires that fulfilled the inclusion criteria.
Study characteristics
In Table 1, an overview of all included studies is provided. Most
itch questionnaires (n=37, 60%) were primarily developed for
dermatological diseases (IFSI category I), followed by systemic
diseases (IFSI category II) with n=19 (31%).Only 2 questionnaires
eachwere developed to assess neuropathic itch (IFSI category III) or
to assess overlapping/coexisting diseases (IFSI categoryVMixed), 2
questionnaires were administered in populations not classified by
IFSI, specifically, the general population[86] and students[85] (Fig. 2).
Around 81% of the included papers were published in the year
2000 or later. Seventy-one percent of the studies had a sample size
over 100 people. The mean age of the individuals included ranged
from 8.9 years for a pediatric questionnaire[51] up to 67 years for a
wound-itching questionnaire[52]. Two of the 62 questionnaires
were especially developed for children[51,81].
The questionnaires were original published in one or more
reported (or presumed) languages. Thirty-one questionnaires were
published in the English language, followed by 8 questionnaires
which were published in the German language. One study was
conducted in Nigeria, here no language was reported or could be
Figure 1. Flow diagram of literature search.
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Table 1
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12-Item Pruritus Severity
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Reich et al[31] 2017 Chronic PD 148 (67:81) 50.0 (15.7) Polish Short
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et al[34]
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2003 AD Total: 400 (214:186) Total: 26.6 (6.8) Japanese Very short
Leuven Itch Scale Haest
et al[47]
2011 BP; AD; CU Total: 150;
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Paul-Pieper-Itching Paul[52] 2013 WP WP with itch: 56
(30:26); WP without
itch: 142 (82:60)
Total: 67 (21–98) English Long
Pruritus questionnaire Weisshaar
et al[53]










2012 DD 110 (44:66) 49 (15) Turkish Short
Psoriasis Symptom Diary Lebwohl
et al[55]




















1986 PGEW 796 (NR) 36.3 (NR) English Short
Rhinitis Symptom Utility Index Revicki
et al[47]
1998 RH 100 (40:60) 36.9 (10.9) English Short
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2001 DD 541 (352:189) 58 (18) English Short
Student Symptom
Questionnaire (school-















Skóry; Index for Atopic
Dermatitis) (by hand
searching)
Silny et al[63] 2005 AD NR NR Polish Very short
Systemic diseases (IFSI category II)
14-item Uraemic Pruritus




2017 UP: ESRD on
HD or PD







234 (80:154) 48 (13.8) English Short
Brief Itching Inventory for UP Mathur
et al[65]
2010 ESRD on HD 103 (53:50) 56 (14.2) English Short
Dialysis itching questionnaire Shirazian
et al[66]







175 (108:67) 48.8 (11.9) English Short
Itch MOS (of sleep) for UP Mathur
et al[65]
2010 ESRD on HD 103 (53:50) 56 (14.2) English Short
Itch questionnaire Rishe et al[68] 2008 PBC Total: 239 (8:231)
PBC with itch: 165 (NR)
PBC without itch: 74 (NR)





2002 HD HD with itch: 49
(20:29); HD without
itch: 21 (9:12)
Itch: 50 (15); no
itch: 54 (14)
English Short
Liver disease symptom index















2005 PBC Validation of the
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assumed because this country has multiple official languages. Seven
questionnaires were very short (2–4 items), 29 were short (5–25
items), 14 questionnaires had a medium size (26–50 items) and 12
questionnaires were long (≥51 items).
Results of individual studies and its synthesis
Table 2 displays the 14 dimensions of itch as defined in the IFSI
SIG itch questionnaires. Around 92% of the questionnaires
consisted of self-report questions filled out by the patient [and
additionally by caregivers in the case of children (Redline, 2003
#5469)]. In 8%, a clinician’s judgment was additionally asked
for. This concerned questions about the origin of pruritus, skin
findings like lesions, previous therapies and investigations as well
as secondary diagnoses. Only 4 questionnaires assessed all
dimensions within the category characteristics of itch (Table 2
and Fig. 3) and none of the questionnaires assessed all dimensions
within the category itch in daily life (Table 2 and Fig. 4).
For the category characteristics of itch, the most frequently
measured dimensions were intensity of itch (65%) followed by
frequency of itch (53%) and localization of itch (52%). Scratch
response and sensory qualities were assessed in only 37% and
26% of the questionnaires, respectively. The dimension of itch
within the category itch in daily life that was most frequently
assessed, was disability (79% of the questionnaires), followed by
quality of life (56%) and itch aggravating or relieving factors
(34%). Of the 49 questionnaires that assessed disability, 74%
asked for itch-related disability, whereas 22% assessed disability
in relation to the patients’ (skin) condition. Itch cognitions and
coping with itch were seldom part of the questionnaires, both in
only 15%. The opinion on the origin of itch was included in only
6% of the questionnaires (Table 1).
Corresponding to the distribution of the questionnaires and the
IFSI-classification, the most assessed dimensions are distributed in
questionnaires administered in conditions classified in the IFSI-I



























1980 HD 53 (NR) NR Spanish Very short
Pruritus questionnaire Balaskas
et al[76]







2013 HES-pts. 190 (105:85) 66 (59–74) Danish Short
Questionnaire Kimme Kimme
et al[78]
2001 HES-pts. 50 (18:32) 52 (11) Swedish Very short
Skindex 10 for UP Mathur
et al[65]
2010 ESRD on HD 103 (53:50) 56 (14.2) English Short





Survey questions Kamimura Kamimura
et al[80]
2017 CLD Total: 41 (15:26); CLD
with itch: 18 (4:14);





















2016 NF1 40 (16:24) 46.5 (20–75) French Medium










2017 BPR 65 (25:40) NR (median:48) Italian Medium





2009 Stud. 840 (420:420) 25 (3.8) NR (administered
in Nigeria)
Medium












Length of questionnaire: very short: 2–4 items, short 5–25 items, medium= 26–50 items, long= ≥ 51 items (1 item is defined as 1 possible answer).
AD indicates atopic dermatitis; BC, breast cancer; BP, burn patients; BPR, back pruritus; CAPD, continuous ambulatory peritoneal dialysis; CC, colon cancer; CLD, chronic liver disease; CU, chronic urticaria; DD,
dermatological diseases; DeMy, dermatomyositis; EB, epidermolysis bullosa; EC, ear complaints; ESRD, end-stage renal disease; HD, hemodialysis; HES, hydroxyethyl starch; HS, hidradenitis suppurativa; IFSI,
International Forum for the Study of Itch; NA, not applicable; NR, not reported; NF1, neurofibromatosis 1; OC, ovarian cancer; PBC, primary biliary cirrhosis; PC, prostate cancer; PD, pruritic dermatoses; PDia,
peritoneal dialysis; PGEW, primary grain elevator workers; PSO, psoriasis; Pts., patients; QoL, quality of life; RH, rhinitis; Stud., students; UP, uremic pruritus; WP, wound patients.
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dermatitis) followed by the IFSI–II category (systemic diseases like
end-stage renal disease or chronic liver disease) (Figs. 3, 4).
Discussion
This review provides a systematic overview of questionnaires that
assess itch. This is an initial step in developing a modular ques-
tionnaire system that can broadly be used to personalize treat-
ments for patients suffering from itch. The majority (60%) of the
62 included itch questionnaires were developed for dermatolo-
gical conditions, followed by 31% developed for systemic itch.
Only 9% of the questionnaires were developed for other itch
conditions and the general population (surveys). None of the
included questionnaires addresses all itch dimensions considered
important by the SIG[1], but most covered both itch-related
characteristics and quality of life. The dimensions localization,
frequency, intensity of itch, and disability were covered by
questionnaires within 5 IFSI-categories. The other dimensions
were included in numerous combinations with high heterogeneity
across questionnaires, which seems generally independent of the
assessed itch condition. Exceptions are the dimension opinion on
origin, which was only included when assessing populations not
classified by IFSI and dermatological diseases[12,57,85,86], itch
cognitions, which was only included in dermatological itch
questionnaires, and response to itch treatment, which was mainly
included in questionnaires for systemic diseases. Notably, the
clinician’s judgment was rarely included and mostly for clinical
skin assessments[12,37,56,84].
Within the category characteristics of itch (Table 2), it is evident
that each questionnaire investigated a specific combination of
dimensions. Only some dermatological questionnaires assessed all
dimensions within this category[12,34,39,56]. When assessing how
each dimension was addressed within the questionnaires, we found
a lot of approaches. Specifically, localization of itchwas frequently
assessed by displaying drawings of the body on which patients had
to indicate the location of their itch[47,64,65], or patients had to circle
which of the listed body parts were itchy[13,69]. For specific condi-
tions, it was often inquiredwhether the itchwas localizedwithin the
body parts affected by the condition, for example, neurofibromas
or rhinitis[58,82]. Frequency of itch was asked for using frames
ranging from one day to multiple weeks. Particularly for postburn
itch, it is essential tomap the frequency of itch per day andweek[87],
as this seems more sensitive to change than intensity given its epi-
sodic nature[88]. Duration of itch was included in less than half of
the questionnaires, of which some only refer to perceived itch
during the day[43,67].Whereas the latter information can be relevant
for some types of itch, for example, postburn itch occurs most often
in the afternoon and evening[88], knowledge on the itch duration
over a longer period is useful to determine whether the itch is acute
or chronic[2]. For most questionnaires, it was even unclear if the
questionnaire was developed for population(s) suffering from acute
or chronic itch or both. Besides, different questionnaires follow
different definitions of chronic itch, for example, itch present for a
minimum of 6 weeks and with episodes occurring (defined by itch
present for 5min several times a day) at least twice a week[43] or
present for at least 3 months[54]. Especially for systemic diseases,
including liver or kidney disease, for which the comorbidity of
chronic itch is lower than in skin conditions such as atopic
dermatitis[5,6,65,89], information about the duration of itch could be
beneficial.
Itch intensitywas assessed inonly 65%of the questionnaires. This is
surprising given its high correlation with the patient’s well-being[88,90].
If included, intensitywas frequently assessedusingaVASorNRS[34,69],
while some questionnaires used Likert scales[31,64]. Despite the major
role scratchingplays in itch and its chronification, for example, the itch-
scratch cycle[91], scratch responses were assessed in about one third
of the questionnaires. Those questions often refer to the effects
of scratching, such as inflicted lesions[39,64], associated feelings[39,65,82],
its frequency[82], or whether scratching occurs intentionally or
automatically[53]. Sensory qualities of itchwere assessed extensively in
some questionnaires[12,39], whereas other questionnaires only included
some sensory (neuropathic-like) descriptors like stabbing or
burning[41,43]. Questions on affective qualities of itch, for example,
annoying, irritating, unbearable, were almost exclusively found in
dermatological questionnaires. Assessing both sensory and affective
descriptors may be useful to distinguish different types of itch[92], for
example, postburn itch has been characterized by neuropathic
descriptors such as stinging, pinching, and burning[93]. Comparable
distinctions have been described for pain[94].
The findings for the category itch in daily life (Table 2) show that
often the effects of itch on daily life were parallelly inquired at a
physical (disability) and emotional (QoL) level. The number of
items addressing these dimensions varied, however, largely; that is,
from 1 item[83], to a unidimensional focus on sleep[65], to a broad
focus of itch on physical and emotional aspects[43,65]. Opinion on
the origin of itchwas predominantly assessed in surveys[57,85,86], for
which the underlying cause of itch varies Itch aggravating or
relieving factors, whether or not actively pursued by the patient,
were primarily assessed in relation to dermatological conditions.
Examples of such factors are sleep, rest, stress, heat[82], different
seasons[68,74], mixing in company to forget the itch, and applying
ointment[39]. Sometimes this was asked in an open question[38]. The
dimensions coping with itch, and cognitions about itchwere barely
included in questionnaires, whilst these are good targets for mul-
tidisciplinary interventions[95]. The response to itch treatments has
incidentally been included, and, proportionally, mainly in relation
to systemic itch diseases[68,69,76,80]. Yet, information about (in)
effectivity of current treatment can be useful to signal if a patient’s
treatment regimen should be adjusted.
A strength of this study is that it for the first time systematically
searched, in multiple databases, for existing itch questionnaires
and that it also provides an overview of which itch dimensions
recommended by IFSI[1] are addressed in these questionnaires. At
Figure 2. Frequencies of itch questionnaires per etiological classification
according to the IFSI. Dermatological diseases according to IFSI category I;
systemic diseases according to IFSI category II; neurological diseases
according to IFSI category III; mixed according to IFSI category V. IFSI indicates
International Forum for the Study of Itch.
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Table 2
Overview of the dimensions of itch acknowledged by the SIG itch Questionnaires[1] that were assessed in the itch questionnaires included in this review (organized per IFSI etiological
classification category in alphabetical order).
Self-report by Patient
Characteristics of Itch Itch in Daily Life
Questionnaire Name References
Clinician’s

















Treatment Coping Cognitions QoL
Dermatological diseases (IFSI category I)




No + + + + + + (+ ) +
2. 4-D score Amtmann
et al[32]
No + + + (+ ) +
3. 5-D-Itch-Scale Elman
et al[13]
No + + + + (+ ) +
4. Adult Burn Outcome
Questionnaire Short Form
Chen et al[33] No + ± + ±
5. AGP-Questionnaire Weisshaar
et al[34]
No + + + + + + + + + (+ ) + + +
6. American Burn Association
Young Adult Burn
Outcome Questionnaire
Ryan et al[35] No + + ± (± ) ±
7. Atopic dermatitis screening
and evaluation
questionnaire
Chen et al[36] No ± ± + + (+ )
8. Brest questionnaire Brenaut
et al[37]
Yes + + + + + + +
9. Burns Itch Questionnaire Van Loey
et al[38]
No + + + + + + (+ ) + +
10. Characteristics of Itch
Questionnaire (adapted





Yes + + + + + + + + + (+ ) +






No + ± (± ) ± ± +
12. Epidermolysis Bullosa and
Pruritus Questionnaire





Yes + + + + + + + + + + (+ ) + + +
14. Impact of Chronic Skin












15. Itch Severity Scale (ISS) Majeski
et al[43]













No + + + (+ )
19. Leuven Itch Scale Haest
et al[47]
No + + + + + + + + (+ ) + +
20. Modified 5-D-Itch-Scale Vossen
et al[48]
No + + + + (+ )





No + + ± ±
23. Parents Symptom
Questionnaire (school-




No + + † ± † ± † ±
24. Paul-Pieper-Itching Paul[52] No + + + + + + +
25. Pruritus questionnaire Weisshaar
et al[53]
No + + + + + + + + +






27. Psoriasis Symptom Diary Lebwohl
et al[55]
No + ± ± +





Yes + + + + + + + + + (+ ) + + +





No ± + ± +
30. Questionnaire survey of
pruritus and rash 1986
Hogan
et al[57]
No + + +




No + + + +
32. Shiratori’s pruritus score Shiratori
et al[59]
No + + + + + (+ )
33. Skindex-61 Chren
et al[60]
No + ± (± ) ± ±
34. Skindex-29 Chren
et al[61]
No + ± ± (± ) ± ±
35. Skindex-16 Chren
et al[62]














Characteristics of Itch Itch in Daily Life
Questionnaire Name References
Clinician’s

















Treatment Coping Cognitions QoL
36. W-AZS (Wskaźnik dla
Atopowego Zapalenia
Skóry; Index for Atopic
Dermatitis)
Silny et al[63] No + + + + + (+ )
37. Student Symptom
Questionnaire (school-




No + † + † + † ± † + †
Systemic diseases (IFSI category II)




No + + + + + + (+ ) +
5-D-Itch-Scale Elman
et al[13]
No + + + + (+ ) +
39. Brief Itching Inventory for UP Mathur
et al[65]










No ± ± + ± ± (± )
42. Itch MOS (of sleep) for UP Mathur
et al[65]
No + (+ )
43. Itch questionnaire Rishe
et al[68]
No + + + + + (+ ) +




No + + + + (+ ) +









No + + +




No + + (+ ) +




No + + (+ ) +
49. Pruritus questionnaire Gilchrest
et al[74]
No + + + + +
50. Pruritus questionnaire Aubia
et al[75]








51. Pruritus questionnaire Balaskas
et al[76]
No + + + + + + + (+ ) +
52. Pruritus questionnaire Wittbrodt
et al[77]
No + +
53. Questionnaire Kimme Kimme
et al[78]
No + + +
54. Skindex 10 for UP Mathur
et al[65]
No + +
55. Survey on uremic pruritus Wikstrom[79] No + (+ ) +
56. Survey questions Kamimura
et al[80]
No + + + +





No ± + (+ ) +




No + § + + + + + + + +





No + + (+ )




Yes + + +





No + + + + + +
62 Prevalence of chronic itch Matterne
et al[86]
No + + + + + + (+ ) + +
+ The questionnaire assesses this dimension of itch.
± The questionnaire assesses this dimension, however not in direct relation to itch, but in relation to the patients’ (skin) condition.
*Only in relation to the ear.
†Only in relation to the eyes, nose or throat.
‡Only in relation to flushing symptoms, that include itch.
§Only in relation to neurofibromas.











the same time, this outline provides an overview of what is still
missing. Such an approach has to our knowledge not yet been
taken in previous reviews, in which, for instance, monodimen-
sional scales or clinical assessments and PROMs were reviewed
for their use in clinical trials[14,15,17]. Another strong point is that
the included questionnaires cover various medical areas, which
we systematically organized in accordance with the IFSI-cate-
gories classifying the underlying diseases.
Several limitations need to be addressed. At first, we aimed at
including papers describing any itch questionnaire for the first
time, but often no measures of reliability and/or validity were
reported. If we were to provide a full overview of these measures,
we should have taken into account all publications of each ques-
tionnaire, for example, in different populations or languages.
When developing a modular questionnaire system, validated and
reliable subscales, derived from studies with low risk of bias
should be included to guarantee quality. Second, for the same
reasons, the current investigation did not focus on whether the
questionnaires were sensitive to change, which is an essential
measure when assessing these dimensions of itch over time. Third,
this inventory only focused on written self-report measures to
assess the different itch dimensions. It is likely that in clinical
practice, next to these measures, also other PROMs as described
in previous reviews[14,15,17] as well as clinician’s judgments on
these dimensions are included. Especially for dermatological dis-
eases, a wide range of clinician’s scores exist that directly or
indirectly relate to itch dimensions, like the SCORAD (SCORing
Atopic Dermatitis)[96], EASI (EczemaArea and Severity Index)[97],
and PASI (Psoriasis Area and Severity Index)[98]. Fourth, we used
the IFSI-classification for chronic itch, irrespective of whether the
questionnaire was developed for acute or chronic itch (if known),
as we are not aware of such classification system for acute itch.
Fifth, a possible bias in this overview is that we excluded papers
based on language restrictions and absence of the full text article
and questionnaire.
To conclude, there is a large number of itch questionnaires,
each with its own focus. The number and content of the items
within a dimension vary greatly and important aspects of itch,
like the intensity, or how responsive the itch is to treatment, are,
remarkably, often not assessed. Moreover, acute and chronic itch
are often not discriminated for in the questionnaires and mea-
surement properties, such as validity, reliability, and capability to
detect change over time, were often not reported by the included
articles. In view of feasibility, it is unlikely that there will be a
questionnaire that includes all itch dimensions and fulfills all
needs. This is why the SIG supports the idea of having a modular
system with some basic questions complemented by additional
modules, for example, for treatment, QoL, etcetera. When
developing such modules, the above described variability should
have to be overcome. As this variability seems largely indepen-
dent of the underlying medical conditions, basic (sub)scales could
probably be used for each dimension, complemented by condi-
tion-specific questions as desired. This way, both general
itch-related information and the demands for specific patient
populations can be investigated in a standardized and compar-
able manner. Future research should focus on gaining agreement
on how to select the (sub)scales for each dimension, in order to
develop modules containing valid and reliable questions that are
sensitive to change. At the same time, usefulness and feasibility in
all kinds of settings, for example, clinic, research, cultural
Figure 3. Number of itch questionnaires including the dimensions within the category “characteristics of itch,” displayed per IFSI etiological classification category.
Dermatological diseases according to IFSI category I; systemic diseases according to IFSI category II; neurological diseases according to IFSI category III; mixed
according to IFSI category V. IFSI indicates International Forum for the Study of Itch.
Figure 4. Number of itch questionnaires including the dimensions within the category “itch in daily life,” displayed per IFSI etiological classification category.
Dermatological diseases according to IFSI category I; systemic diseases according to IFSI category II; neurological diseases according to IFSI category III; mixed
according to IFSI category V. IFSI indicates International Forum for the Study of Itch.
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suitability[99], should be taken into account. This hopefully leads
to improved care for patients suffering from itch.
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